백신 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Vaccines Market - Scope of Report

TMR's report on the global vaccines market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global vaccines market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global vaccines market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the vaccines market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global vaccines market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global vaccines market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global vaccines market.

The report delves into the competitive landscape of the global vaccines market. Key players operating in the global vaccines market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global vaccines market profiled in this report.

Key Questions Answered in Global vaccines Market Report:

• What is the sales/revenue generated by vaccines across all regions during the forecast period?
• What are the opportunities in the global vaccines market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Vaccines Market - Research Objectives and Research Approach

The comprehensive report on the global vaccines market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global vaccines market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global vaccines market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Vaccines Market

4. Market Overview

• 4.1. Introduction
• 4.2. Definition
• 4.3. Industry Evolution / Developments
• 4.4. Overview
• 4.5. Market Dynamics
  • 4.5.1. Drivers
  • 4.5.2. Restraints
  • 4.5.3. Opportunities
• 4.6. Global Vaccines Market Analysis and Forecast, 2017-2031
  • 4.6.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Regulatory Scenario
• 5.2. Key Distribution Strategies
• 5.3. Pricing Analysis
• 5.4. Patents on Vaccines
• 5.5. Technological Advancements in Vaccines
• 5.6. Vaccine Type - Overview
• 5.7. COVID-19 Pandemic Impact on Industry

6. Global Vaccines Market Analysis and Forecast, by Vaccine

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Vaccine, 2017-2031
  • 6.3.1. Inactivated
  • 6.3.2. Live Attenuated
  • 6.3.3. Toxoid
  • 6.3.4. Conjugate
  • 6.3.5. Others
• 6.4. Market Attractiveness Analysis, by Vaccine

7. Global Vaccines Market Analysis and Forecast, by Valance

• 7.1. Introduction & Definition
• 7.2. Developments
• 7.3. Market Value Forecast, by Valance, 2017-2031
  • 7.3.1. Monovalent
  • 7.3.2. Multivalent
• 7.4. Market Attractiveness Analysis, by Valance

8. Global Vaccines Market Analysis and Forecast, by Route of Administration

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Route of Administration, 2017-2031
  • 8.3.1. Oral
  • 8.3.2. Injectable
  • 8.3.3. Others
• 8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Vaccines Market Analysis and Forecast, by Indication

• 9.1. Introduction & Definition
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by Indication, 2017-2031
  • 9.3.1. Influenza
  • 9.3.2. Hepatitis
  • 9.3.3. Polio
  • 9.3.4. Meningococcal Disease
  • 9.3.5. Pneumococcal Disease
  • 9.3.6. DTP
  • 9.3.7. Rotavirus
  • 9.3.8. MMR
  • 9.3.9. Human Papilloma Virus
  • 9.3.10. Others
• 9.4. Market Attractiveness Analysis, by Indication

10. Global Vaccines Market Analysis and Forecast, by Distribution Channel

• 10.1. Introduction & Definition
• 10.2. Key Findings/Developments
• 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 10.3.1. Institutional Sales
  • 10.3.2. Hospital Pharmacies
  • 10.3.3. Retail Pharmacies
• 10.4. Market Attractiveness Analysis, by Distribution Channel

11. Global Vaccines Market Analysis and Forecast, by Region

• 11.1. Key Findings
• 11.2. Market Value Forecast, by Region, 2017-2031
  • 11.2.1. North America
  • 11.2.2. Europe
  • 11.2.3. Asia Pacific
  • 11.2.4. Latin America
  • 11.2.5. Middle East & Africa
• 11.3. Market Attractiveness Analysis, by Region

12. North America Vaccines Market Analysis and Forecast

• 12.1. Introduction
• 12.2. Key Findings
• 12.3. Market Value Forecast, by Vaccine, 2017-2031
  • 12.3.1. Inactivated
  • 12.3.2. Live Attenuated
  • 12.3.3. Toxoid
  • 12.3.4. Conjugate
  • 12.3.5. Others
• 12.4. Market Value Forecast, by Valance, 2017-2031
  • 12.4.1. Monovalent
  • 12.4.2. Multivalent
• 12.5. Market Value Forecast, by Route of Administration, 2017-2031
  • 12.5.1. Oral
  • 12.5.2. Injectable
  • 12.5.3. Others
• 12.6. Market Value Forecast, by Indication, 2017-2031
  • 12.6.1. Influenza
  • 12.6.2. Hepatitis
  • 12.6.3. Polio
  • 12.6.4. Meningococcal Disease
  • 12.6.5. Pneumococcal Disease
  • 12.6.6. DTP
  • 12.6.7. Rotavirus
  • 12.6.8. MMR
  • 12.6.9. Human Papilloma Virus
  • 12.6.10. Others
• 12.7. Market Value Forecast, by Distribution Channel, 2017-2031
  • 12.7.1. Institutional Sales
  • 12.7.2. Hospital Pharmacies
  • 12.7.3. Retail Pharmacies
• 12.8. Market Value Forecast, by Country/sub-region, 2017-2031
  • 12.8.1. U.S.
  • 12.8.2. Canada
• 12.9. Market Attractiveness Analysis
  • 12.9.1. By Vaccine
  • 12.9.2. By Valance
  • 12.9.3. By Route of Administration
  • 12.9.4. By Indication
  • 12.9.5. By Distribution Channel
  • 12.9.6. By Country

13. Europe Vaccines Market Analysis and Forecast

• 13.1. Introduction
• 13.2. Key Findings
• 13.3. Market Value Forecast, by Vaccine, 2017-2031
  • 13.3.1. Inactivated
  • 13.3.2. Live Attenuated
  • 13.3.3. Toxoid
  • 13.3.4. Conjugate
  • 13.3.5. Others
• 13.4. Market Value Forecast, by Valance, 2017-2031
  • 13.4.1. Monovalent
  • 13.4.2. Multivalent
• 13.5. Market Value Forecast, by Route of Administration, 2017-2031
  • 13.5.1. Oral
  • 13.5.2. Injectable
  • 13.5.3. Others
• 13.6. Market Value Forecast, by Indication, 2017-2031
  • 13.6.1. Influenza
  • 13.6.2. Hepatitis
  • 13.6.3. Polio
  • 13.6.4. Meningococcal Disease
  • 13.6.5. Pneumococcal Disease
  • 13.6.6. DTP
  • 13.6.7. Rotavirus
  • 13.6.8. MMR
  • 13.6.9. Human Papilloma Virus
  • 13.6.10. Others
• 13.7. Market Value Forecast, by Distribution Channel, 2017-2031
  • 13.7.1. Institutional Sales
  • 13.7.2. Hospital Pharmacies
  • 13.7.3. Retail Pharmacies
• 13.8. Market Value Forecast, by Country/sub-region, 2017-2031
  • 13.8.1. Germany
  • 13.8.2. U.K.
  • 13.8.3. France
  • 13.8.4. Italy
  • 13.8.5. Spain
  • 13.8.6. Rest of Europe
• 13.9. Market Attractiveness Analysis
  • 13.9.1. By Vaccine
  • 13.9.2. By Valance
  • 13.9.3. By Route of Administration
  • 13.9.4. By Indication
  • 13.9.5. By Distribution Channel
  • 13.9.6. By Country/Sub-region

14. Asia Pacific Vaccines Market Analysis and Forecast

• 14.1. Introduction
• 14.2. Key Findings
• 14.3. Market Value Forecast, by Vaccine, 2017-2031
  • 14.3.1. Inactivated
  • 14.3.2. Live Attenuated
  • 14.3.3. Toxoid
  • 14.3.4. Conjugate
  • 14.3.5. Others
• 14.4. Market Value Forecast, by Valance, 2017-2031
  • 14.4.1. Monovalent
  • 14.4.2. Multivalent
• 14.5. Market Value Forecast, by Route of Administration, 2017-2031
  • 14.5.1. Oral
  • 14.5.2. Injectable
  • 14.5.3. Others
• 14.6. Market Value Forecast, by Indication, 2017-2031
  • 14.6.1. Influenza
  • 14.6.2. Hepatitis
  • 14.6.3. Polio
  • 14.6.4. Meningococcal Disease
  • 14.6.5. Pneumococcal Disease
  • 14.6.6. DTP
  • 14.6.7. Rotavirus
  • 14.6.8. MMR
  • 14.6.9. Human Papilloma Virus
  • 14.6.10. Others
• 14.7. Market Value Forecast, by Distribution Channel, 2017-2031
  • 14.7.1. Institutional Sales
  • 14.7.2. Hospital Pharmacies
  • 14.7.3. Retail Pharmacies
• 14.8. Market Value Forecast, by Country/sub-region, 2017-2031
  • 14.8.1. China
  • 14.8.2. India
  • 14.8.3. Japan
  • 14.8.4. Australia & New Zealand
  • 14.8.5. Rest of Asia Pacific
• 14.9. Market Attractiveness Analysis
  • 14.9.1. By Vaccine
  • 14.9.2. By Valance
  • 14.9.3. By Route of Administration
  • 14.9.4. By Indication
  • 14.9.5. By Distribution Channel
  • 14.9.6. By Country/Sub-region

15. Latin America Vaccines Market Analysis and Forecast

• 15.1. Introduction
• 15.2. Key Findings
• 15.3. Market Value Forecast, by Vaccine, 2017-2031
  • 15.3.1. Inactivated
  • 15.3.2. Live Attenuated
  • 15.3.3. Toxoid
  • 15.3.4. Conjugate
  • 15.3.5. Others
  • 15.3.6. Others
• 15.4. Market Value Forecast, by Valance, 2017-2031
  • 15.4.1. Monovalent
  • 15.4.2. Multivalent
• 15.5. Market Value Forecast, by Route of Administration, 2017-2031
  • 15.5.1. Oral
  • 15.5.2. Injectable
  • 15.5.3. Others
• 15.6. Market Value Forecast, by Indication, 2017-2031
  • 15.6.1. Influenza
  • 15.6.2. Hepatitis
  • 15.6.3. Polio
  • 15.6.4. Meningococcal Disease
  • 15.6.5. Pneumococcal Disease
  • 15.6.6. DTP
  • 15.6.7. Rotavirus
  • 15.6.8. MMR
  • 15.6.9. Human Papilloma Virus
  • 15.6.10. Others
• 15.7. Market Value Forecast, by Distribution Channel, 2017-2031
  • 15.7.1. Institutional Sales
  • 15.7.2. Hospital Pharmacies
  • 15.7.3. Retail Pharmacies
• 15.8. Market Value Forecast, by Country/sub-region, 2017-2031
  • 15.8.1. Brazil
  • 15.8.2. Mexico
  • 15.8.3. Rest of Latin America
• 15.9. Market Attractiveness Analysis
  • 15.9.1. By Vaccine
  • 15.9.2. By Valance
  • 15.9.3. By Route of Administration
  • 15.9.4. By Indication
  • 15.9.5. By Distribution Channel
  • 15.9.6. By Country/Sub-region

16. Middle East & Africa Vaccines Market Analysis and Forecast

• 16.1. Introduction
• 16.2. Key Findings
• 16.3. Market Value Forecast, by Vaccine, 2017-2031
  • 16.3.1. Inactivated
  • 16.3.2. Live Attenuated
  • 16.3.3. Toxoid
  • 16.3.4. Conjugate
  • 16.3.5. Others
• 16.4. Market Value Forecast, by Valance, 2017-2031
  • 16.4.1. Monovalent
  • 16.4.2. Multivalent
• 16.5. Market Value Forecast, by Route of Administration, 2017-2031
  • 16.5.1. Oral
  • 16.5.2. Injectable
  • 16.5.3. Others
• 16.6. Market Value Forecast, by Indication, 2017-2031
  • 16.6.1. Influenza
  • 16.6.2. Hepatitis
  • 16.6.3. Polio
  • 16.6.4. Meningococcal Disease
  • 16.6.5. Pneumococcal Disease
  • 16.6.6. DTP
  • 16.6.7. Rotavirus
  • 16.6.8. MMR
  • 16.6.9. Human Papilloma Virus
  • 16.6.10. Others
• 16.7. Market Value Forecast, by Distribution Channel, 2017-2031
  • 16.7.1. Institutional Sales
  • 16.7.2. Hospital Pharmacies
  • 16.7.3. Retail Pharmacies
• 16.8. Market Value Forecast, by Country/sub-region, 2017-2031
  • 16.8.1. GCC Countries
  • 16.8.2. South Africa
  • 16.8.3. Rest of Middle East & Africa
• 16.9. Market Attractiveness Analysis
  • 16.9.1. By Vaccine
  • 16.9.2. By Valance
  • 16.9.3. By Route of Administration
  • 16.9.4. By Indication
  • 16.9.5. By Distribution Channel
  • 16.9.6. By Country/Sub-region

17. Competition Landscape

• 17.1. Market Player Competition Matrix (by tier and size of companies)
• 17.2. Market Share Analysis, by Company (2022)
• 17.3. Company Profiles
  • 17.3.1. AstraZeneca
    • 17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.1.2. Product Portfolio
    • 17.3.1.3. Financial Overview
    • 17.3.1.4. SWOT Analysis
    • 17.3.1.5. Strategic Overview
  • 17.3.2. GlaxoSmithKline PLC
    • 17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.2.2. Product Portfolio
    • 17.3.2.3. Financial Overview
    • 17.3.2.4. SWOT Analysis
    • 17.3.2.5. Strategic Overview
  • 17.3.3. Sanofi Pasteur SA
    • 17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.3.2. Product Portfolio
    • 17.3.3.3. Financial Overview
    • 17.3.3.4. SWOT Analysis
    • 17.3.3.5. Strategic Overview
  • 17.3.4. Pfizer Inc.
    • 17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.4.2. Product Portfolio
    • 17.3.4.3. Financial Overview
    • 17.3.4.4. SWOT Analysis
    • 17.3.4.5. Strategic Overview
  • 17.3.5. Panacea Biotec
    • 17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.5.2. Product Portfolio
    • 17.3.5.3. Financial Overview
    • 17.3.5.4. SWOT Analysis
    • 17.3.5.5. Strategic Overview
  • 17.3.6. Merck & Co., Inc.
    • 17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.6.2. Product Portfolio
    • 17.3.6.3. Financial Overview
    • 17.3.6.4. SWOT Analysis
    • 17.3.6.5. Strategic Overview
  • 17.3.7. Janssen Pharmaceutical Company
    • 17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.7.2. Product Portfolio
    • 17.3.7.3. Financial Overview
    • 17.3.7.4. SWOT Analysis
    • 17.3.7.5. Strategic Overview
  • 17.3.8. Serus Institute of India Ltd
    • 17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.8.2. Product Portfolio
    • 17.3.8.3. Financial Overview
    • 17.3.8.4. SWOT Analysis
    • 17.3.8.5. Strategic Overview
  • 17.3.9. Emergent BioSolutions Inc.
    • 17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.9.2. Product Portfolio
    • 17.3.9.3. Financial Overview
    • 17.3.9.4. SWOT Analysis
    • 17.3.9.5. Strategic Overview
  • 17.3.10. CSL
    • 17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.10.2. Product Portfolio
    • 17.3.10.3. Financial Overview
    • 17.3.10.4. SWOT Analysis
    • 17.3.10.5. Strategic Overview
  • 17.3.11. Bavarian Nordic
    • 17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.11.2. Product Portfolio
    • 17.3.11.3. Financial Overview
    • 17.3.11.4. SWOT Analysis
    • 17.3.11.5. Strategic Overview
  • 17.3.12. IBSS BIOMED S.A.
    • 17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.12.2. Product Portfolio
    • 17.3.12.3. Financial Overview
    • 17.3.12.4. SWOT Analysis
    • 17.3.12.5. Strategic Overview
  • 17.3.13. Novavax AB
    • 17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.13.2. Product Portfolio
    • 17.3.13.3. Financial Overview
    • 17.3.13.4. SWOT Analysis
    • 17.3.13.5. Strategic Overview
  • 17.3.14. Mitsubishi Tanabe Pharma Corporation
    • 17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.14.2. Product Portfolio
    • 17.3.14.3. Financial Overview
    • 17.3.14.4. SWOT Analysis
    • 17.3.14.5. Strategic Overview